Nivolumab (240 mg)

DRUG4 trials

Sponsors

Biogen, National Taiwan University Hospital, Zhejiang Haichang Biotech Co., Ltd., Prof. Lars Olaf Cardell

Conditions

Esophageal CancerEsophageal Squamous Cell CarcinomaHepato Cellular Carcinoma (HCC)MelanomaMetastatic (Stage IV) MelanomaOral Squamous Cell Carcinoma (OSCC)Renal Cell CancerUnresectable (Stage III) Melanoma

Phase 1

RTA 408 Capsules in Patients With Melanoma - REVEAL

CompletedNCT02259231

BiogenMelanoma, Metastatic (Stage IV) Melanoma, Unresectable (Stage III) Melanoma

Start: 2014-10-31End: 2018-07-23Updated: 2025-06-04

Phase 2

Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma

RecruitingNCT07152678

National Taiwan University HospitalEsophageal Cancer, Esophageal Squamous Cell Carcinoma

Start: 2025-09-30End: 2028-09-30Target: 60Updated: 2025-09-03

Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

Not yet recruitingNCT07494435

Zhejiang Haichang Biotech Co., Ltd.Hepato Cellular Carcinoma (HCC), Renal Cell Cancer

Start: 2026-06-01End: 2028-09-01Target: 230Updated: 2026-03-27

Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma

Not yet recruitingNCT07514767

Prof. Lars Olaf CardellOral Squamous Cell Carcinoma (OSCC)

Start: 2026-05-01End: 2033-09-01Target: 60Updated: 2026-04-07

Related Papers

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.

2017-08-2938 citations